vaccines are performing, rather than clinical trial data, and the data sets all show how the delta variant has blunted the effectiveness of both the Pfizer and AstraZeneca jabs," said Simon Clarke, an associate professor in cellular microbiology at the University of Reading.
Pfizer's shot remained less effective in comparison with AstraZeneca at preventing infections with a high viral burden in roughly 4.5 months after the second dose, said Koen Pouwels, an Oxford senior researcher who helped lead the study. “The higher levels of virus that we’re seeing in these infections in vaccinated people are consistent with the fact that unvaccinated people are just going to be at higher risk, I’m afraid," said Sarah Walker, a professor of medical